The whole process management strategy of irreversible electroporation in the treatment of liver cancer

Abstract

Abstract: Since 2015, irreversible electroporation has been introduced and approved for clinical use in China. So far, some large-scale centers and their experts in China have accumulated rich experience in the application of this technology. However, as a new technology, there are still many blind spots and misunderstandings in its technical promotion and clinical application. Therefore, this paper mainly discusses the basic principles and advantages of irreversible electroporation in the treatment of liver cancer, preoperative case screening, intraoperative operative points, postoperative management, efficacy evaluation, safety and complications, technical disadvantages and limitations, and makes a prospect for the future of irreversible electroporation.

Key words: Irreversible electric ablation technology, Liver cancer, Whole process management strategy

Wu Huiming, Zhao Jianjun. The whole process management strategy of irreversible electroporation in the treatment of liver cancer[J]. Electronic Journal of Liver Tumor, 2021, 8(2): 57-61.

References

[1] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].肝癌电子杂志,2020,7(1):5-23.
[2] TORRE L A, BRAY F, SIEGEL R L, et al.Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[3] LAI EC, FAN ST, LO CM, et al.Hepatic resection for hepatocellular carcinoma. An audit of 343 patients[J]. Ann Surg, 1995, 221: 291-298.
[4] FORNER A, REIG M, BRUIX J.Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314.
[5] NIESSEN C, THUMANN S, BEYER L, et al.Percutaneous irreversible electroporation: long-term survival analysis of 71 patients with inop-erable malignant hepatic tumors[J]. Sci Rep, 2017, 7: 43687
[6] WAGSTAFF P G, BRUIN D D, ZONDERVAN P J, et al.The efficacy and safety of irreversible electroporation for the ablation of renal masses: a prospective, human, in-vivo study protocol[J]. Bmc Cancer, 2015, 15(1): 165.
[7] LEE E W, D WONG, PRIKHODKO S V, et al. Electron Microscopic Demonstration and Evaluation of Irreversible Electroporation-Induced Nanopores on Hepatocyte Membranes[J]. J Vasc Interv Radiol. 2012, 23(1): 107-113.
[8] CHANG D C, REESE T S.Changes in membrane structure induced by electroporation as revealed by rapid-freezing electron microscopy[J]. Biophys J, 1990, 58(1): 1-12.
[9] RUBINSKY B.Irreversible electroporation in medicine[J]. Technol Cancer Res Treat, 2007, 6(4): 255.
[10] LU D, RAMAN S S, LIMANOND P, et al.Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors[J]. J Vasc Interv Radiol, 2003, 14(10): 1267-1274.
[11] YU N C, RAMAN S S, KIM Y J, et al.Microwave Liver Ablation: Influence of Hepatic Vein Size on Heat-sink Effect in a Porcine Model[J]. J Vasc Interv Radiol, 2008, 19(7): 1087-1092.
[12] BHUTIANI N, PHILIPS P, SCOGGINS CR, et al.Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child- Pugh B (7/8) hepatocellular carcinoma (HCC)[J]. HPB (Oxford), 2016, 18(7), 593-599.
[13] 郭凯,李晓勇,周百中,等.纳米刀消融治疗不可切除肝门部胆管癌的临床价值[J]. 中国普通外科杂志,2020,35(1):78-84.
[14] Narayanan G,Fround T.Pain Analysis in Patients with Hepatocellular Carcinoma: Irreversible Electroporation versus Radiofrequency Ablation—Initial Observations[J]. Cardiovasc Intervent Radiol, 2013, 36(1): 176-182.
[15] VERLOH N, JENSCH I, LüRKEN L, et al. Similar complication rates for irreversible electroporation and thermal ablation in patients with hepatocellular tumors[J]. Radiol Oncol. 2019, 53(1): 116-122.
[16] LEE E W, LOH C T, K EE S T. Imaging Guided Percutaneous Irreversible Electroporation: Ultrasound and Immunohistological Correlation[J]. Technol Cancer Res Treat, 2016, 6(4): 287-294.
[17] SUTTER O, CALVO J, G N'KONTCHOU, et al. Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series[J]. Radiology, 2017: 877-886.
[18] THOMSON KR, CHEUNG W, ELLIS SJ, et al.Investigation of the safety of irreversible electroporation in humans[J]. Vasc Interv Radiol, 2011, 22: 611-621.
[19] FRÜHLING P,NILSSON A. Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results[J]. Eur J Surg Oncol, 2017, 43(4): 751-757.
[20] ASHA Z, DAVID G, KEVIN C.Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives[J]. J Hepatocell Carcinoma, 2017, 4: 49-58.
[21] NIESSEN C, JULIANE IGL.et al.Factors Associated with Short-Term Local Recurrence of Liver Cancer after Percutaneous Ablation Using Irreversible Electroporation: A Prospective Single-Center Study[J]. J Vasc Interv Radiol, 2015, 26(5): 694-702.
[22] BALL C, THOMSON K R, KAVNOUDIAS H.Irreversible Electroporation: A New Challenge in "Out of Operating Theater" Anesthesia[J]. Anesth Analg, 2010, 110(5): 1305-1309.
[23] TILBORG A, VIEVEEN J M, KUIJK C V, et al.Anaesthetic management during open and percutaneous irreversible electroporation[J]. Br J Anaesth, 2014, 113(6): 985-992.
[24] MARTIN R C, SCHWARTZ E, ADAMS J A, et al.Intra - operative Anesthesia Management in Patients Undergoing Surgical Irreversible Electroporation of the Pancreas, Liver, Kidney, and Retroperitoneal Tumors[J]. Anesth Pain Med, 2015, 5(2): e22786.
[25] CAI Z, CHEN G, ZENG Y, et al.Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma[J]. Clin Cancer Res, 2019, 25(17): 5284-5294.
[26] CAI Z X, CHEN G, ZENG Y Y, et al.Circulating tumor DNA profiling reveals clonal evolution and real‐time disease progression in advanced hepatocellular carcinoma[J]. Int J Cancer, 2017, 141(5): 977-985
[27] DOLLINGER M, BEYER L P, HAIMERL M, et al.Adverse effects of irreversible electroporation of malignant liver tumors under CT fluoroscopic guidance: a single-center experience[J]. Diagn Interv Radiol, 2015, 21(6): 471.
[28] DISTELMAIER M, BARABASCH A, HEIL P, et al.Midterm Safety and Efficacy of Irreversible Electroporation of Malignant Liver Tumors Located Close to Major Portal or Hepatic Veins[J]. Radiology, 2017, 285(3): 1023-1031.
[29] WAGSTAFF PG, DE BRUIN DM, VAN DEN BOS W, et al. Irreversible electroporation of the porcine kidney: Temperature development and distribution[J]. Urol Oncol, 2015, 33(4): 168. e1-7.
[30] CHEN X, REN Z, YIN S, et al.The local liver ablation with pulsed electric field stimulate systemic immune reaction against hepatocellular carcinoma (HCC) with time-dependent cytokine profile[J]. Cytokine, 2017,93: 44-50.
[31] LI X, XU K, LI W, et al.Immunologic Response to Tumor Ablation with Irreversible Electroporation[J]. Plos One, 2012, 7(11): e48749.
[32] BE B ULVIK, ROZENBLUM N, GOUREVICH S, et al.Irreversible Electroporation versus Radiofrequency Ablation: A Comparison of Local and Systemic Effects in a Small-Animal Model[J]. Radiology, 2016, 280(2): 413.